Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Winfastorlose who wrote (1252374)	8/5/2020 10:00:22 PM
From: Wharf Rat	Respond to of 1573041

"I can’t understand how the Democrats can field someone that they will just have to impeach if he ever got into office." Good. That's part of the plan.

To: Winfastorlose who wrote (1252374)	8/5/2020 10:20:50 PM
From: FJB	3 Recommendations Recommended By IC720 Thomas M. Winfastorlose Read Replies (1) \| Respond to of 1573041

The treatment group has 79.1% lower chance of death. Early treatment with hydroxychloroquine: a country-randomized controlled trial @CovidAnalysis Many countries either adopted or declined early treatment with HCQ, forming a large country-randomized controlled trial. 2.0 billion people were assigned to the treatment group, and 663 million to the control group. As of August 5, 2020, an average of 37.8/million in the treatment group have died, and 438.5/million in the control group, relative risk 0.086. After adjustments, treatment and control deaths become 78.2/million and 626.6/million, relative risk 0.12. Confounding factors affect this estimate, including varying degrees of spread between countries. Accounting for predicted changes in spread, we estimate a relative risk of 0.21. The treatment group has 79.1% lower chance of death. We examined diabetes, obesity, hypertension, life expectancy, population density, urbanization, testing level, and intervention level, which do not account for the effect observed.